CIM
CLB icon

Contravisory Investment Management’s Core Laboratories CLB Stock Holding History

Contravisory Investment Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-28
Closed -$3K – 448
2017
Q3 		$3K Buy
+28
New +$2.71K ﹤0.01% 324
2017
Q2 		– Sell
-28
Closed -$3K – 162
2017
Q1 		$3K Hold
28
– – ﹤0.01% 241
2016
Q4 		$3K Hold
28
– – ﹤0.01% 229
2016
Q3 		$3K Buy
+28
New +$3.23K ﹤0.01% 223

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Contravisory Investment Management's CLB Position: Q4 2017 in Review

Contravisory Investment Management sold out of Core Laboratories (CLB) in Q4 2017, closing a stake of 28 shares — an estimated $3K sold.

Contravisory Investment Management first reported a position in CLB in Q3 2016 and held it in 4 quarters. The position peaked at $3K in Q3 2017. 356 funds tracked by Wall St. Rank hold CLB as of Q4 2017.

  • Contravisory Investment Management reported no remaining Core Laboratories position as of Q4 2017 after selling out during the quarter.
  • Contravisory Investment Management sold 28 Core Laboratories shares in Q4 2017, an estimated $3K.
  • Contravisory Investment Management first reported a position in Core Laboratories in Q3 2016 and held it in 4 quarters.
  • Contravisory Investment Management's Core Laboratories position peaked at $3K in Q3 2017.
  • 356 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2017.

Based on Contravisory Investment Management's 13F filing for Q4 2017, filed 18 Jan 2018.